Evidence map›Paper›PMID 32462681›Full record

ArticleJournal of surgical oncology2020

Impact of tumor regression grade on recurrence after preoperative chemoradiation and gastrectomy for gastric cancer.

Alexander P Stark, Jeannelyn S Estrella, Yi-Ju Chiang, Prajnan Das, Bruce D Minsky, Mariela A Blum Murphy, Jaffer A Ajani, Paul Mansfield, Brian D Badgwell, Naruhiko Ikoma

Open access · greenAbstract read
In one paragraph

Article in Journal of surgical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Comparison of the predictive value of pathological response at primary tumor and lymph node status after neoadjuvant chemotherapy in locally advanced gastric cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Alexander P StarkDepartments of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID http://orcid.org/0000-0001-8463-5414
Jeannelyn S EstrellaDepartments of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID http://orcid.org/0000-0003-3705-5964
Yi-Ju ChiangDepartments of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Prajnan DasDepartments of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Bruce D MinskyDepartments of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Mariela A Blum MurphyDepartments of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jaffer A AjaniDepartments of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Paul MansfieldDepartments of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Brian D BadgwellDepartments of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID http://orcid.org/0000-0002-9915-8355
Naruhiko IkomaDepartments of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID http://orcid.org/0000-0002-9825-9234
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672NIH HHS P30CA016672
6 · The paper itself

Abstract

BACKGROUND AND

objectivesIt is unknown whether the degree of response to preoperative therapy correlates with locoregional recurrence (LR) or distant recurrence (DR) after resection of gastric cancer.

methodsPatients who underwent resection of gastric adenocarcinoma following chemotherapy and chemoradiation (1995-2015) were reviewed. The tumor regression grade (TRG) was defined by the percentage of viable tumor cells in the specimen (TRG0 = 0%; TRG1 = 1%-2%; TRG2 = 3%-50%; TRG3 ≥ 50%). The relationships among TRG, recurrence-free survival (RFS), LR, and DR were examined.

resultsTwo hundred forty-seven patients met the inclusion criteria (TRG0, 52 [21%]; TRG1, 49 [20%]; TRG2, 98 [40%]; TRG3, 48 [19%]). LR and DR occurred in 6.1% and 32.0% of patients, respectively. No patient with TRG0 experienced LR. R1 resection (6%-15%) and LR (6%-8%) rates were similar among TRG1-3 patients. R1 resection was associated with LR (hazard ratio [HR], 17.85; P < .001). ypN status (HR, 2.44; P = .004) and linitis plastica (HR, 2.90; P < .001) were associated with DR. TRG was not independently associated with RFS, LR, or DR.

conclusionsTRG0 imparted excellent local control. However, TRG1-3 patients had similar R1 resection rates and therefore similar LR. DR is associated with ypN status and linitis plastica, not TRG.

Indexed as

AgedChemoradiotherapyDisease-Free SurvivalFemaleGastrectomyHumansMaleMiddle AgedNeoadjuvant TherapyNeoplasm Recurrence, LocalNeoplasm StagingProportional Hazards ModelsStomach NeoplasmsTexasgastric cancerneoadjuvantradiation therapyrecurrencetumor regression grade

Identifiers

PMID32462681
PMCPMC7731155
OpenAlexW3028858632

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.